Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. - Hurley RM; McGehee CD; Nesic K; Correia C; Weiskittel TM; Kelly RL; Venkatachalam A; Hou X; Pathoulas NM; Meng XW; Kondrashova O; Radke MR; et al. (NAR cancer, 2021)